CalciMedica, Inc.
CALC · XNASCIK 1534133fmd_063DWNKF845F2RWFF3A8ZKEDPHManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2019 to Sep 30, 2026, 31 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Research and development | 31 | 21 | 19 | 8 | 16 | 14 | 15 |
| Non-interest income | – | – | – | – | – | 1 | 1 |
| Total operating expenses | 38 | 30 | 36 | 14 | 38 | 24 | 23 |
| Operating income | (38) | (30) | (36) | (14) | (38) | (24) | (23) |
| Interest expense | – | – | – | – | – | 0 | 1 |
| Interest and investment income | 0 | 0 | 0 | 1 | – | – | – |
| Other non-operating income (expense) | – | – | – | 6 | 4 | 11 | (6) |
| Income before taxes | – | – | – | – | – | (14) | (30) |
| Income tax expense | – | – | – | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | – | – | – | – | (14) | (30) |
| Net income | (37) | (28) | (36) | (8) | (34) | (14) | (30) |
| Net income to common shareholders | (44) | (35) | (36) | (9) | (34) | (14) | (30) |